Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma

Feline mammary carcinomas are characterized by rapid progression and metastases. Vascular endothelial growth factor (VEGF) is a key regulator of tumor angiogenesis, proliferation and metastasis. The present study aimed to investigate the effects of a single drug therapy of bevacizumab on a xenograft...

Descripción completa

Detalles Bibliográficos
Autores principales: MICHISHITA, Masaki, OHTSUKA, Aya, NAKAHIRA, Rei, TAJIMA, Tsuyoshi, NAKAGAWA, Takayuki, SASAKI, Nobuo, ARAI, Toshiro, TAKAHASHI, Kimimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Veterinary Science 2015
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873862/
https://www.ncbi.nlm.nih.gov/pubmed/26616000
http://dx.doi.org/10.1292/jvms.15-0550
Descripción
Sumario:Feline mammary carcinomas are characterized by rapid progression and metastases. Vascular endothelial growth factor (VEGF) is a key regulator of tumor angiogenesis, proliferation and metastasis. The present study aimed to investigate the effects of a single drug therapy of bevacizumab on a xenograft model of feline mammary carcinoma expressing VEGF protein. Bevacizumab treatment suppressed tumor growth by inhibiting angiogenesis and enhancing apoptosis; however, it did not affect the tumor proliferation index. Thus, bevacizumab had anti-tumor effects on a xenograft model, and this may be useful for the treatment of feline mammary carcinoma.

Ejemplares similares